Esben Juhl Hansen

Learn More
Within recent years data has accumulated demonstrating the efficacy of recombinant interferon alpha2 (rIFN-alpha2) in the treatment of chronic myeloproliferative neoplasms (MPNs). We report on clinical and molecular data in the largest cohort of JAK2 V617F mutant MPN Danish patients (n=102) being treated long-term with rIFN-alpha2 (rIFN-alpha2a and(More)
OBJECTIVE To evaluate the onset of analgesic effect for a new formulation of ibuprofen sodium dihydrate versus conventional ibuprofen (ibuprofen acid). MATERIALS AND METHODS In this randomized, double-blind, double-dummy, crossover trial, patients requiring surgical removal of two impacted or partially impacted mandibular third molars received: ibuprofen(More)
BB has received research funding from Celgene and Millennium, is a consultant to Celgene and Millennium, and is a co-inventor on patents and patent applications related to use of GEP in cancer medicine that have been licensed to Myeloma Health, LLC. SZU is a consultant to Celgene, Millennium and Onyx. He has received research funding from Onyx and Celgene,(More)
AIM To retrospectively evaluate the 1-year outcome of implant therapy involving various types of localised lateral alveolar ridge and/or sinus floor augmentation procedures performed before implant placement. MATERIALS AND METHODS Forty-seven patients were consecutively treated with oral implants on average 6.5 months after bone grafting. A total of 82(More)
  • 1